Crux of Medtech: A New Vital Sign for Heart Failure with Filip Peters, CEO of Acorai
In this episode of the Crux of Cardio, host Jordan Bergen sits down with Filip Peters, Co-founder and CEO of Acorai, to unpack how his team is building a non-invasive device that reads the pressures inside the heart, using machine learning inspired by oil and gas diagnostics.
Filip shared the full founder journey: from garage prototypes in Sweden through COVID, to a 1,600-patient study across six countries and FDA Breakthrough Device designation.
He explained why Acorai chose to focus on the hospitalised heart failure workflow over remote monitoring, and broke down the economics that make every heart failure admission a loss for US hospitals.
Filip also discussed the challenges of fundraising in today’s market, navigating EU MDR as an AI-enabled device, and his advice for cardiovascular founders on staying in “science project mode” for as long as possible.
